Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

    Not Recruiting
  • End date
    May 31, 2027
  • participants needed
  • sponsor
    NRG Oncology
Updated on 2 June 2021
Keisha Humphries, RN
Primary Contact
Cancer Center of Kansas-Independence (0.0 mi away) Contact
+334 other location
breast cancer
endocrine therapy
hormone therapy
gynecologic cancer
ductal carcinoma in situ


This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer. Bupropion hydrochloride may work by boosting sexual desire, energy, or motivation without causing intolerable or undesirable side effects.



I. Measure the ability of two dose levels of bupropion hydrochloride (bupropion), 150 or 300 mg of extended release, to improve sexual desire more than a placebo at 9 weeks (8 weeks on the target dose) as measured by the desire subscale of the female sexual function index (FSFI).


I. Evaluate the side effects of 150 and 300 mg bupropion extended release and differentiate these side effects from those observed in the placebo arm.

II. Evaluate the effect of 150 and 300 mg of bupropion extended release on the Patient Reported Outcomes Measurement Information System (PROMIS) fatigue scale, PROMIS sexual desire and satisfaction measure, patient health questionnaire (PHQ)-4, and the FSFI total score, at 5 and 9 weeks, as well as the desire subscale score of the FSFI at 5 weeks.

III. Evaluate the effect of 150 and 300 mg of bupropion extended release on the global impression of change scale and the patient?s perception of risk versus (vs.) benefit at 5 weeks (4 weeks at target dose) and 9 weeks (8 weeks at target dose).

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM A: Patients receive bupropion hydrochloride orally (PO) once daily (QD) on days 1-63 and placebo PO QD on days 8-71.

ARM B: Patients receive bupropion hydrochloride PO QD on days 1-7 and 64-71, and twice daily (BID) on days 8-63.

ARM C: Patients receive placebo PO QD on days 1-7 and 64-71, and BID on days 8-63.

Condition Ductal Carcinoma In Situ, Cervical Cancer, Breast Cancer, Ovarian Cancer, Cervical Intraepithelial Neoplasia, Vaginal Cancer, Postmenopausal, Uterine Corpus Cancer, Vulvar Carcinoma, Recurrent Ovarian Cancer, Ductal Carcinoma In Situ (DCIS)
Treatment Placebo, Bupropion Hydrochloride
Clinical Study IdentifierNCT03180294
SponsorNRG Oncology
Last Modified on2 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note